Shots:
- AI is redefining visibility in pharma as it becomes the primary gateway to information, requiring companies to shift from content publishing to engineering discoverability with machine-readable, well-cited, and rapidly updated data to be included in AI-generated summaries
- Integrated, structured evidence is now critical for success in AI-driven environments, demanding modular, metadata-rich, and consistent data across clinical, commercial, and access functions with early cross-functional alignment to deliver a unified and trustworthy narrative
- PharmaShots welcomes Ben Beckley, CEO of RevHealth, for an insightful conversation on how AI is reshaping decision-making, transforming patient journeys, and driving the need for strong data governance, bias monitoring, and ecosystem-driven content strategies in healthcare
Saurabh: AI is rapidly embedding itself into healthcare infrastructure in 2026. From your vantage point at RevHealth, what fundamentally changes for pharmaceutical companies when AI becomes a primary gateway to clinical and brand information?
Ben: When AI becomes the gateway, search behavior shifts from browsing to synthesized answers. We are already seeing zero-click rates increase, meaning searchers are never making it to company, brand, or disease websites for more information. The information is simply displayed in the AI search results.
That means pharma is no longer competing only for impressions. It is competing for inclusion in an algorithm’s summary layer. The first implication is that if your evidence isn’t machine-readable, it won’t surface. The second is that authority shifts from brand voice to citation density. AI prioritizes validated, referenced, cross-confirmed data. Third, speed matters more. AI systems update rapidly, so if your data lags, competitors can quickly fill the vacuum.
The core shift is that pharma moves from publishing content to engineering discoverability. That is where RevHealth has been helping companies navigate the complexity and engineer resources that AI systems can interpret and surface correctly.
Saurabh: As physicians increasingly rely on AI-enabled clinical decision tools, how must pharma rethink the structure, accessibility, and validation of scientific evidence to remain visible and credible in AI-driven environments?
Ben: Evidence now has to be designed for ingestion, not just publication. First, data needs to be modularized with clear endpoints, subgroups, safety signals, and transparent methodology.
Second, structured metadata has to be embedded so AI systems can interpret context correctly.
Third, consistency across channels becomes critical, including label information, congress data, HEOR outputs, and real-world evidence.
Physicians are unlikely to read 40-page manuscripts in AI-driven workflows. They will increasingly rely on distilled outputs generated by AI systems. That means pharma has to ensure that what those systems summarize is accurate, complete, and representative of the evidence. In this environment, visibility will increasingly correlate with the clarity and structure of the data itself.
Saurabh: Rare disease markets already struggle with information asymmetry. How does AI-mediated discovery intensify or potentially solve this challenge?
Ben: It can actually do both. On one hand, AI can accelerate pattern recognition across fragmented symptoms, reduce diagnostic delay through cross-dataset signal detection, and improve global awareness of niche therapeutic options.
At the same time, it can reinforce bias if the training data underrepresents certain populations or oversimplifies nuanced treatment decisions. The opportunity is enormous because AI has the potential to democratize expertise that historically has been concentrated in a small number of academic centers. But that opportunity only works if there is deliberate attention to data inclusion and strong validation discipline.
Saurabh: In an AI-shaped ecosystem, should medical, commercial, and market access teams converge earlier in launch planning? How is RevHealth guiding clients to operationalize that integration in practice?
Ben: Yes. Not eventually. Immediately.
AI-driven ecosystems do not separate clinical, value, and access narratives. Algorithms synthesize across all three simultaneously. If those teams operate sequentially, the message will appear in fragmented moments.
At RevHealth, we guide clients to align the scientific narrative, the value story, and the access strategy inside one integrated framework. This is also reflected in how we built the agency. We do not organize around business units or divisions. Experts across these disciplines converge at the same time on the same topic so that the narrative remains consistent and fluid for different audiences, including AI systems interpreting the information.
We build launch architectures that anticipate AI-mediated queries and design content ecosystems that support multiple stakeholders from a single validated data core. Launch planning can no longer be linear. It has to function as a system.
Saurabh: How should pharma leaders assess the risks of algorithmic filtering, bias, or incomplete data representation when AI influences physician and patient decision-making?
Ben: Pharma needs to treat AI platforms as new intermediaries in the healthcare system. Leaders should start by asking several critical questions.
First, what data sources are training the systems influencing our stakeholders?
Second, are our pivotal data sets represented accurately?
Third, where might bias exclude certain populations or treatment options? Fourth, do we have monitoring in place for AI-generated misinformation, or partners who can monitor this for us?
At RevHealth, we believe this requires an ongoing surveillance mindset rather than a one-time audit. Ignoring algorithmic bias is not neutral. It is strategically negligent.
Saurabh: With patients consulting conversational AI platforms before seeing specialists, how is the traditional patient journey being redefined particularly in specialty and rare conditions?
Ben: What we are seeing increasingly is that patients arrive at specialists pre-informed and sometimes, in their own minds, pre-diagnosed by AI tools. That changes the patient’s mindset before the consultation even begins. Expectations are higher, awareness of potential treatments is greater, and patients often feel more confident asking for a specific course of care.
In specialty and rare conditions, AI can compress years of uncertainty into months. At the same time, it can create false confidence if the information is incomplete or misinterpreted. The traditional journey was physician-led discovery. The emerging journey is AI-primed consultation. Manufacturers need to support credible and accessible information earlier in the journey, well before the point of prescription.
Saurabh: How should agencies and manufacturers redesign content strategies so that clinical, value, and access narratives remain discoverable across AI-powered platforms?
Ben: Content strategies need to shift from being campaign-centric to ecosystem-centric. The first step is structuring data so AI platforms can accurately interpret it. That includes ensuring that clinical, economic, and access narratives are interconnected rather than treated as separate streams.
Another important step is designing content with citation integrity and a clear hierarchy of evidence so that AI systems recognize the authority and reliability of the information. Finally, organizations should develop authoritative hubs that serve as reference anchors for AI systems drawing information from multiple sources.
In AI environments, discoverability is not driven by volume. It is earned through structure, credibility, and clarity of evidence.
Saurabh: What core organizational capabilities, spanning data governance, digital fluency, and cross-functional integration must pharma companies develop now to remain competitive in an AI-mediated landscape?
Ben: First is data governance. Companies need clean, harmonized, machine-readable evidence supported by strong validation controls.
Second is digital fluency. Leaders need to understand how AI systems ingest, rank, and synthesize information, or they need trusted partners who do. There also needs to be cross-functional AI literacy across the organization. AI cannot sit inside a single innovation or digital team. At RevHealth, for example, AI is part of everyone’s workflow rather than the responsibility of one department.
Third is cross-functional integration. Organizations need a unified launch architecture that connects evidence generation with commercial reality and recognizes the importance of early HEOR and market access alignment.
AI will reward companies that think systemically rather than operating through fragmented launch models.
Saurabh: As RevHealth works across medical strategy, marketing, and market access, what are the most urgent strategic questions executive teams should be asking today to safeguard launch visibility, stakeholder trust, and competitive positioning in an AI-driven healthcare landscape?
Ben: We encourage pharma partners to start with a set of practical questions:
- First, are we designing our evidence for AI discoverability?
- Second, do our medical, commercial, and access narratives reinforce each other?
- Third, where could algorithmic bias distort our story?
- Fourth, how quickly can we update and validate data across channels, ideally in real time or close to it?
- Fifth, who owns AI visibility inside the organization, and do we have the right partners to support that work?
Ultimately, the companies that succeed will not be the ones with the loudest voice. They will be the ones whose data is structured, credible, and strategically engineered to surface within AI-mediated decision environments.
About Ben Beckley
CEO of RevHealth
Ben is a passionate advocate for health equity, dedicated to improving outcomes for underserved patient communities. He is deeply committed to nurturing the next generation of leaders, empowering them to drive meaningful, experience-led change in healthcare. Inspired by his work alongside patients, caregivers, and leading specialists, Ben brings a thoughtful and forward-looking perspective to creating impactful solutions that truly make a difference.
Related Post: Turning Genome Data into Clinical Insight: Jehee Suh of Inocras on AI-Driven Genomics
